GlassScriptPhysician profile
Anam Mazharuddin
NPI 1508356858
$2,750.78
in general payments reported to CMS, 2019-2025
25 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.29 · 2021: $23.40 · 2022: $768 · 2023: $664 · 2024: $639 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.06 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $223.82 | 2021-2025 | Clareon, Hydrus Microstent, Eysuvis |
| Horizon Therapeutics Plc | $182.60 | 2022-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $173.82 | 2022-2025 | Miebo, Vyzulta, Alrex |
| Ocular Therapeutix, INC. | $158.22 | 2023-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $135.46 | 2023-2025 | Cequa |
| Allergan, INC. | $124.49 | 2022 | |
| Rxsight INC | $116.46 | 2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Amgen INC. | $113.01 | 2024 | Tepezza |
| Sight Sciences, INC. | $106.47 | 2022-2025 | Omni Surgical System |
| Oyster Point Pharma, INC. | $104.70 | 2022-2024 | Tyrvaya |
| Biotissue Holdings INC. | $98.55 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $92.41 | 2024-2025 | Xdemvy |
| Astrazeneca Pharmaceuticals LP | $81.29 | 2019 | |
| Harrow Eye, LLC | $74.36 | 2024-2025 | Vevye |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $70.16 | 2022-2023 | |
| Thea Pharma INC. | $65.16 | 2022-2025 | Iyuzeh |
| Dompe US, INC. | $57.21 | 2022-2025 | Oxervate |
| Pharmacosmos Therapeutics INC. | $20.39 | 2025 | Monoferric |
| Rayner Intraocular Lenses Limited | $19.65 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
| New World Medical,INC. | $18.92 | 2025 | Streamline, Via360, Kahook Dual Blade |
| Daiichi Sankyo INC. | $18.17 | 2025 | Datroway |
| Carl Zeiss Meditec USA, INC. | $15.92 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $13.38 | 2022 | |
| Astellas Pharma US INC | $13.10 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anam Mazharuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.